Cargando…

How Many Diseases Are Colorectal Cancer?

The development of personalised therapy and mechanism-targeted agents in oncology mandates the identification of the patient populations most likely to benefit from therapy. This paper discusses the increasing evidence as to the heterogeneity of the group of diseases called colorectal cancer. Differ...

Descripción completa

Detalles Bibliográficos
Autores principales: Greystoke, A., Mullamitha, S. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444041/
https://www.ncbi.nlm.nih.gov/pubmed/22991509
http://dx.doi.org/10.1155/2012/564741
_version_ 1782243618734473216
author Greystoke, A.
Mullamitha, S. A.
author_facet Greystoke, A.
Mullamitha, S. A.
author_sort Greystoke, A.
collection PubMed
description The development of personalised therapy and mechanism-targeted agents in oncology mandates the identification of the patient populations most likely to benefit from therapy. This paper discusses the increasing evidence as to the heterogeneity of the group of diseases called colorectal cancer. Differences in the aetiology and epidemiology of proximal and distal cancers are reflected in different clinical behaviour, histopathology, and molecular characteristics of these tumours. This may impact response both to standard cytotoxic therapies and mechanism-targeted agents. This disease heterogeneity leads to challenges in the design of clinical trials to assess novel therapies in the treatment of “colorectal cancer.”
format Online
Article
Text
id pubmed-3444041
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-34440412012-09-18 How Many Diseases Are Colorectal Cancer? Greystoke, A. Mullamitha, S. A. Gastroenterol Res Pract Review Article The development of personalised therapy and mechanism-targeted agents in oncology mandates the identification of the patient populations most likely to benefit from therapy. This paper discusses the increasing evidence as to the heterogeneity of the group of diseases called colorectal cancer. Differences in the aetiology and epidemiology of proximal and distal cancers are reflected in different clinical behaviour, histopathology, and molecular characteristics of these tumours. This may impact response both to standard cytotoxic therapies and mechanism-targeted agents. This disease heterogeneity leads to challenges in the design of clinical trials to assess novel therapies in the treatment of “colorectal cancer.” Hindawi Publishing Corporation 2012 2012-09-09 /pmc/articles/PMC3444041/ /pubmed/22991509 http://dx.doi.org/10.1155/2012/564741 Text en Copyright © 2012 A. Greystoke and S. A. Mullamitha. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Greystoke, A.
Mullamitha, S. A.
How Many Diseases Are Colorectal Cancer?
title How Many Diseases Are Colorectal Cancer?
title_full How Many Diseases Are Colorectal Cancer?
title_fullStr How Many Diseases Are Colorectal Cancer?
title_full_unstemmed How Many Diseases Are Colorectal Cancer?
title_short How Many Diseases Are Colorectal Cancer?
title_sort how many diseases are colorectal cancer?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444041/
https://www.ncbi.nlm.nih.gov/pubmed/22991509
http://dx.doi.org/10.1155/2012/564741
work_keys_str_mv AT greystokea howmanydiseasesarecolorectalcancer
AT mullamithasa howmanydiseasesarecolorectalcancer